Our commitment to improve life for patients and their families is our highest priority. Working with medicines for rare diseases means that many of these patients do not have any other options and the medicines that we supply may be crucial for the patients’ future. Many of the people living with a rare disease are children. Collaboration with partner organizations is important for Immedica to be able to gain important insights. We work both with local national organizations as well as PAN European networks.
Patient safety and quality is at the core of our business and is part of a medicine’s journey from development and into real world use. We ensure the quality throughout the manufacturing, supply, and distribution of Immedica products. We are committed to make sure our products have positive benefit risk profile, which includes optimizing the benefit of the treatments we provide, as well as protecting patients from unnecessary harm. We regularly monitor and evaluate our compliance with our internal procedures as well as applicable legislation, and the need for any improvements are discussed and actioned via governance structures which involve the executive management team. Immedica is regularly audited and inspected by partners and competent authorities on a regular basis with the target to meet both ethical and legal requirements and no findings which may pose a risk to public health and our patients.
Partnerships are one of our cornerstones and to continue to develop our current partnerships and to initiate new ones are essential for the continued growth of our company. We have high ambitions to deliver excellence in partnering. Due to this we conduct an annual partner satisfaction survey, which is very important for us to develop together with our partners.
